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Background: The single most distressing symptom for patients with advanced esophageal cancer is dysphagia.
Amongst the more effective treatments for relief of dysphagia is insertion of a self-expanding metal stent (SEMS). It
is possible that the addition of a palliative dose of external beam radiotherapy may prolong the relief of dysphagia
and provide additional survival benefit. The ROCS trial will assess the effect of adding palliative radiotherapy after
esophageal stent insertion.
Methods/Design: The study is a randomized multicenter phase III trial, with an internal pilot phase, comparing stent
alone versus stent plus palliative radiotherapy in patients with incurable esophageal cancer. Eligible participants are
those with advanced esophageal cancer who are in need of stent insertion for primary management of dysphagia.
Radiotherapy will be administered as 20 Gray (Gy) in five fractions over one week or 30 Gy in 10 fractions over two
weeks, within four weeks of stent insertion. The internal pilot will assess rates and methods of recruitment; pre-agreed
criteria will determine progression to the main trial. In total, 496 patients will be randomized in a 1:1 ratio with follow
up until death. The primary outcome is time to progression of patient-reported dysphagia. Secondary outcomes
include survival, toxicity, health resource utilization, and quality of life. An embedded qualitative study will explore the
feasibility of patient recruitment by examining patients’ motivations for involvement and their experiences of consent
and recruitment, including reasons for not consenting. It will also explore patients’ experiences of each trial arm.
Discussion: The ROCS study will be a challenging trial studying palliation in patients with a poor prognosis. The
internal pilot design will optimize methods for recruitment and data collection to ensure that the main trial is
completed on time. As a pragmatic trial, study strengths include collection of all follow-up data in the usual place of
care, and a focus on patient-reported, rather than disease-orientated, outcomes. Exploration of patient experience and
health economic analyses will be integral to the assessment of benefit for patients and the NHS.
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Trial registration: The trial was registered with Current Controlled Trials (registration number: ISRCTN12376468) on
10 July 2012.
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Esophageal cancer resulted in 7,606 deaths in the United
Kingdom in 2008, reflecting a 70% increase in male age-
standardized mortality rates compared to 1971. It is the
sixth most common cause of cancer deaths (fourth in men)
and incidence rates are increasing by 4.2% per annum [1].
Prognosis is poor, with five-year survival rates of 10 to 15%
[2]. It is predominately a disease of the elderly, with preva-
lence highest in the seventh and eighth decades of life.
Most patients present with incurable disease, and for ad-
vanced disease, mean survival is three to five months [3].
The emphasis of treatment for the majority of patients is
therefore on effective palliative interventions, with 70 to
90% requiring intervention for dysphagia [4,5]. This single
symptom has profound impact on social and physical func-
tioning and other aspects of quality of life (QoL). Interven-
tions to improve swallowing must therefore aim to produce
prompt and lasting palliation of dysphagia whilst minimiz-
ing the need for late re-interventions and hospitalization.
Interventions must produce these benefits without causing
significant impairment of other aspects of QoL.
The most recent Cochrane systematic review [6] of inter-
ventions for dysphagia in esophageal cancer confirms the
efficacy of self-expanding metal stents (SEMS) in providing
rapid initial relief of dysphagia, with fewer adverse effects
and lower re-intervention rates than endoscopic ablative
therapies.
A health technology assessment (HTA) [7] also highlights
the efficacy of stent placement. However, delayed complica-
tions are common and result in later re-interventions. A
pragmatic study as part of that assessment found that 35%
of patients receiving stents required re-interventions [8].
Homs et al. [9] in a comparative study of brachytherapy
described a hemorrhage rate of 13% in patients treated with
a stent within a median of 123 days post-insertion. Conio
et al. [10] in a randomized comparison of two stent types
described tumor overgrowth in 19% within a median of 97
days post-insertion.
It is such late re-interventions and complications which
account for the major proportion of dysphagia treatment
costs [8], requiring travel to hospital and inpatient stays
which also impair QoL. This is consistent with estimations
that healthcare costs in general in the last year of life
account for 20 to 30% of overall healthcare budgets [11].
Of the non-stent interventions, brachytherapy studies
[9,12] suggest this treatment gives longer dysphagia-free
survival and more stable QoL compared to a stent.However, a recent survey by the Royal College of Radiolo-
gists (London, United Kingdom) showed that brachyther-
apy treatment for all tumor sites accounts for only 2.5% of
all radiotherapy patients. There is little access to, or expert-
ise in, this type of radiotherapy for esophageal cancer
patients in the United Kingdom [13]. In contrast, external
beam radiotherapy is readily accessible by patients at re-
gional cancer centers across the United Kingdom, although
its use in the immediate post-stent period has not been
rigorously studied and is not routinely used.
Available evidence therefore suggests that a stent is an
appropriate intervention for rapid dysphagia relief in
incurable esophageal cancer. The efficacy of stent alone,
however, is limited by early problems with pain, decline in
general aspects of QoL, and later complications such as
hemorrhage and tumor overgrowth. Re-interventions not
only impose significant burden on NHS resources but de-
crease the QoL and functioning of an unwell, predominantly
elderly, population. Combination with other treatments
might reduce costs and patient burden; for example the
addition of radiotherapy may ameliorate these problems and
provide additional survival benefit.
Given the sporadic and consistently limited availability of
brachytherapy in the United Kingdom, the overarching aim
of this study is to address uncertainties in the current evi-
dence base by assessing whether the addition of external
beam radiotherapy prolongs improvement in dysphagia,
improves QoL, and reduces health economic and personal
burden in patients undergoing stent placement.
Main research question
The main study aim is to assess the impact of palliative
radiotherapy in addition to stent placement on the time to
progression of patient-reported dysphagia in a patient
population unable to undergo surgery or radical chemo-
radiotherapy. We will also examine the impact on overall
survival, serious adverse events (SAEs), toxicity, QoL, and
cost effectiveness. The feasibility of patients’ recruitment to
the trial will be examined in the internal pilot phase and the
participants’ experience of the trial participation and inter-
ventions will be explored in the qualitative research study.
Methods/Design
This will be a pragmatic, randomized controlled trial, with
an internal pilot phase, of external beam radiotherapy in
addition to stent versus stent alone in patients clinically
assessed as requiring stent insertion for the relief of
Figure 1 Trial schema. Integrated pilot phase aims: that at least 70% of patients referred for SEMS are eligible for the study and that at least
50% consent to randomization. SEMS: Self Expanding Metal Stent; GI MDT: Gastrointestinal MDT; EBRT: External Beam Radiotherapy; Gy: Gray.
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pliance with the Helsinki declaration, the Radiotherapy
after Oesophageal Cancer Stenting (ROCS) study has been
granted ethical approval by the Southeast Wales Research
Ethics Committee (reference number: 12/WA/0230).
The target population will be patients selected by an
upper gastrointestinal multidisciplinary team (MDT) for
palliation of malignant dysphagia with an esophageal
stent. Patients will be identified in secondary care,
including cancer centers and district general hospitals,
from 10 participating centers. All study centers have been
chosen on the basis of number of patients supported by
the MDT and potential recruitment rates, as well as
interest in the study. Geographical spread has also
been an important consideration, in recognition of higherincidence rates of esophageal cancer in particular parts of
the United Kingdom including Scotland, North Wales,
and Northwest England.
Internal pilot
This is a pragmatic study in a patient group who are likely
to be frail and elderly. To ensure that study recruitment is
feasible, and that study conduct is optimized, the trial
incorporates an internal pilot phase. The study will be
limited to five centers in the first year, with continuation
of the study dependent on demonstration of feasibility as
defined by the following rules agreed by discussion within
the trial management group: (1) at least 70% of patients
undergoing stent placement as primary treatment for
esophageal cancer dysphagia are considered eligible for
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and (2) at least 50% of eligible patients consent to
randomization in the first nine months of recruitment.
A screening log will record the details of patients who are
or are not screened in full for trial entry, and the precise
reasons for ineligibility. The screening log will also record
details of eligible participants who do not consent to
randomization. The log will be used to understand barriers
to trial recruitment and patient preferences. Anonymized
data will be returned centrally on a monthly basis for
review. A lead research practitioner will be part of the trial
team to support research nurses at other sites and organize
national meetings to review screening data, share best
practice, and where appropriate, make recommendations
for change. Following review, centers may be contacted as
appropriate if potentially eligible patients are not being fully
screened, or if many patients are being classified as
ineligible. Site visits by the lead nurse will consider these
details and discuss with the site team as necessary to ensure
that recruitment of all patients potentially eligible for the
trial is maintained. Qualitative assessments to understand
patient experience of the recruitment process, focusing on
non-consenting patients in the pilot phase, will further
inform study conduct.Participant eligibility
Patients meeting the following nine criteria may be included
in the trial: (1) have histological confirmation of esophageal
carcinoma excluding small-cell carcinoma histology, (2) are
not suitable for radical treatment (esophagectomy or radical
chemo-radiotherapy) either because of patient choice or
medical reasons, (3) have dysphagia clinically assessed as
needing a stent as primary treatment of the dysphagia, (4)
be aged 16 years or over, (5) discussion and treatment
decision for stent (SEMS) placement made by an upper
gastrointestinal multi-disciplinary team, (6) ability to attend
for radiotherapy as determined by clinician assessment, (7)
an expected survival time of at least 12 weeks, (8) willing to
provide written informed consent, and (9) has completed
baseline QoL questionnaires (as a minimum patients
must have completed the Oesophago-Gastric 25 (OG25)
questionnaire).
Patients meeting any of the following eight exclusion
criteria will be excluded from the study: (1) have histology
of small-cell carcinoma type; (2) have a tumor length of
greater than 12 cm; (3) have tumor growth within 2 cm of
the upper esophageal sphincter; (4) have endoscopic treat-
ment of the tumor, other than dilatation, planned during
the peri-stent period; (5) have a tracheo-esophageal fistula;
(6) have a pacemaker in the proposed radiotherapy field;
(7) have undergone previous radiotherapy in the area of
the proposed radiotherapy field; (8) or are a female patient
who is pregnant.Recruitment and randomization
Eligible participants will be identified and approached in
secondary care including cancer centers and district general
hospitals. The patient’s consent to participate in the trial
will be obtained prior to any trial-related procedures, which
includes the insertion of a stent, and after a full explanation
of the treatment options has been given. Consent will be
taken by an appropriately trained research nurse or dele-
gate. Patients who consent to randomization will also be
asked to consent to NHS Information Centre flagging so
that the date and cause of death can be collected without
longer term follow-up. This will be optional and additional
to the standard informed consent.
Patients who decline to participate in the main study, as
well as participants who enter the main study, will be asked
whether they consent to the storage of their contact details
so that a qualitative researcher may contact them to invite
them to participate in a qualitative interview about the
reasons behind their decision not to participate in the main
trial, or of their experiences of the interventions, as appro-
priate. Patients who agree to the storage of their contact
details will be asked to sign the appropriate section of the
main consent form. At this time, they will also be given a
separate qualitative interview patient information sheet and
consent form to take home and read. The qualitative
researcher will collect consent for conducting the interview
immediately prior to commencement of the interview,
using the qualitative interview consent form.
Patients will be randomized centrally by the Wales
Cancer Trials Unit prior to stent insertion using the
method of minimization, which includes a random elem-
ent. Patients will be stratified for a number of clinically
important factors. The randomization allocation ratio for
control to intervention arms will be 1:1 and the embedded
qualitative component of the study will also explore pa-
tients’ perceptions and experiences of the randomization
process.
Study interventions
The SEMS procedure for both arms will be as follows: a
stent will be inserted, following the decision by the MDT to
proceed with stenting as the primary treatment for the
dysphagia. Insertion will be in accordance with the standard
procedures of the treating centre. The length and type will
be determined by the responsible clinician. The following
will be recorded: whether the stent is inserted under
sedation or general anaesthetic, whether dilatation is
required before or after stent insertion, and whether radio-
logical imaging is used. Where possible the length of stent
will be chosen to ensure that at least 2 cm of normal
esophagus is covered by the stent above and below the
tumor stricture. Where necessary, more than one stent
may be deployed. A post-insertion esophagogram may be
used to confirm stent position and exclude perforation.
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normal procedure for stent insertion is permitted. The
trial should not be offered to patients who are deemed to
need or are offered routine endoscopic treatment of the
tumor (such as endoscopic laser therapy) in the immedi-
ate peri-stenting period, unless an emergency situation
arises that requires such a procedure. Brachytherapy or
external beam radiotherapy should not be planned to be
given routinely after stent insertion for those patients in
the control arm. Patients will be stratified according to the
prior use of systemic chemotherapy.
External beam radiotherapy treatment for the interven-
tion arm will begin within four weeks after stent insertion.
Radiotherapy will be delivered using a simple technique
(usually a parallel opposed pair of beams) with either a dose
of 20 Gy in five fractions over one week, or 30 Gy in 10
fractions over two weeks, prescribed to the mid-point of
the irradiated volume, using daily fractionation and the
center’s normal radiotherapy treatment procedures. The
dose and fractionation schedule chosen will be at the
discretion of the treating clinical oncologist. Treatment will
normally be received as an outpatient.
If the patient misses more than seven consecutive
calendar days during radiotherapy treatment, then they
should be withdrawn from the intervention and further
treatment given at the clinician’s discretion. In the unlikely
event of radiotherapy side effects severe enough to
interfere with treatment delivery, the treating clinician
may temporarily stop treatment and allow a break of no
more than seven calendar days prior to recommencement.
The Radiotherapy Quality Assurance (RTQA) will be car-
ried out by the Cardiff National Cancer Research Institute
(NCRI) Radiotherapy Trials Quality Assurance (RTTQA)
Group. RTQA accreditation is required by all centers, but
due to the simple nature of the radiotherapy delivered in
this trial, will not be extensive and will consist of pre-trial
and on-trial quality assurance.
Pre-trial quality assurance
A process document is to be completed by the radiotherapy
site prior to being opened to recruitment. This should con-
tain information on set-up, verification, and beam arrange-
ment. This will be reviewed by the ROCS RTQA group.
The national radiotherapy trials quality assurance baseline
questionnaire should be returned to the NCRI RTTQA
group, if not updated within the last two years.
On-trial quality assurance
Following entry of the first patient into the trial at a
radiotherapy treatment site, a set of CT images or
simulator images, together with information concerning
the treatment fields (Digital Imaging and Communications
in Medicine-RadioTherapy file or hard copy) and treated
volumes should be forwarded to the ROCS RTQA group.Assessments and outcomes
A research practitioner will collect baseline data prior to
stent insertion, one week following stent insertion, four
weeks post stent insertion (and after radiotherapy in the
intervention arm) and four-weekly thereafter until death.
Dedicated research staff will visit patients at home or a
place of their choice and the patients will be asked to
complete the questionnaires themselves whenever possible.
The assessments at baseline will be measured using
WHO performance status, QoL questionnaires (European
Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire C30(EORTC QLQ-C30), EORTC
QLQ-OG25, EuroQuol-5D (EQ-5D)) and the toxicity
assessment Common terminology Criteria for Adverse
Events (CTCAE) v4.03.
The assessment performed within one week of stent
insertion will be measured using WHO performance status,
questionnaires (EORTC QLQ-C30, EORTC QLQ-OG25,
EQ-5D), the toxicity assessment (CTCAE v4.03), stent mor-
bidity data, and a qualitative interview (subset of patients).
The assessments performed four weeks after stent
insertion and four-weekly thereafter until death will be mea-
sured using the WHO performance status, questionnaires
(EORTC QLQ-C30, EORTC QLQ-OG25, EQ-5D), the
toxicity assessment (CTCAE v4.03), stent morbidity data,




This will be measured at the specified time points using
the EORTC QLQ-OG25 questionnaire. The QLQ-OG25
is an updated and improved questionnaire [14] that
amalgamates the widely-used EORTC scales to assess
health-related quality of life (HRQoL) in patients with
esophageal and gastric cancer [15,16]. Dysphagia has
been chosen because it is the dominant symptom in
advanced esophageal cancer and the aim of treatment
is to alleviate this problem effectively and maintain
effective swallowing for as long as possible. The new
questionnaire has six scales and the dysphagia scale is
scored from 0 to 100; a change of 10 to 15 points is
considered clinically significant [17].
Relief of dysphagia is expected in the majority of
participants following stent insertion. A dysphagia score
will be taken at baseline (prior to the stent insertion) and
then one week after stent insertion (prior to radiotherapy
in the intervention arm). This second measurement will
form the ‘time zero’ measurement for the main endpoint
of the study. If no improvement from baseline of more
than 11 points is observed at the ‘time zero’ measurement,
then patients will remain in the study but will be
documented as a failure at ‘time zero’ and will undergo
further interventions undertaken at the discretion of the
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at four weeks after stent insertion, and at four-weekly
intervals after that. The time point at which an 11-point
deterioration is seen in the dysphagia scores compared to
the ‘time zero’ measurement will form the event for the
primary outcome. Following this time point (progression
in dysphagia), patients will continue to be followed up on
four-weekly until death. It is possible that patients
undergoing radiotherapy may have a temporary worsening
of dysphagia secondary to radiation-induced esophagitis,
and other temporary changes might occur. This will be
important to capture. However, to ensure that it does not
bias the primary outcome, definitive deterioration in
dysphagia will be defined as an 11-point change on two
consecutive occasions, with the first being taken as
the event time point. If there is missing data at that
subsequent assessment, deterioration will be assumed
and timed at the previous assessment.
Secondary outcome measures
Quality of life
QoL will be measured using the EORTC QLQ-C30,
EORTC QLQ-OG25, and EQ-5D at the time points
described. The EORTC QLQ-C30 has become a benchmark
measure of QoL in cancer patients. This measure will be
employed in addition to QLQ-OG25 as validation of the
latter. Lagergren et al. [14] demonstrated that they measure
separate HRQoL issues, and it is likely that dysphagia only
accounts for a proportion of QoL impact [18]. The EQ-5D
[19] is a short QoL tool which is designed to complement
other QoL measures, and is recommended by the National
Institute for Health and Care Excellence (NICE) for use in
providing an index of HRQoL for generation of economic
analyses.
Survival
Notification of death will be collected and overall survival
will be calculated from the date of randomization to the
date of death from any cause. Participants remaining alive
will be censored at the date of last follow-up.
Morbidity
Overall length of hospital stay, complication rates,
number of blood transfusions, and re-intervention
rates will be gathered from case notes and captured
in the case report forms. Early complications will be
defined as those occurring within seven days of the
intervention, and late complications will be defined as those
occurring more than seven days after the intervention.
Standard definitions of stent complications will be clearly
described in the protocol.
Toxicity data will be scored using the National Cancer
Institute CTCAE v4.03 and the Radiation Therapy
Oncology Group acute/late questionnaire at baseline,during treatment, and at the pre-specified time points
on follow-up. SAEs will be monitored in real-time by the
chief investigator and trial management group (TMG.)
Data will also be collected on symptom burden including
pain, eating restrictions, and physical functioning via the
EORTC QLQ-C30 and QLQ-OG25 scales.
Cost effectiveness
The economic evaluation will be in the form of a cost
utility analysis assessing total costs against differences
in HRQoL. This is the form of economic evaluation
preferred by the NICE [20]. In line with NICE guidance,
the analysis will be undertaken from an NHS and Personal
Social Services perspective.
HRQoL will be assessed using EQ-5D which is a single
index utility-based measure [21]. Quality-adjusted life
years (QALYs) will be derived from the group differences
in EQ-5D scores between baseline (after adjusting for any
baseline differences [22]) and death using the area under
the curve method. EQ-5D has been used previously to
study patients with inoperable esophageal cancer [8].
Costs associated with stent insertion are not relevant to
the study question. The only direct cost of the interven-
tion is that associated with the delivery of radiotherapy
which will be delivered according to centre protocols. The
primary source of unit costs for radiotherapy will be the
relevant NHS tariffs [23].
Data on total NHS resource use will be collected
prospectively by the research nurses at baseline and
at all time points specified above, via a combination
of case note review and patient recall, and valued
using relevant unit costs. Due to likely skewness, cost data
will be bootstrapped [24]. Patient-borne costs, including
travel to receive radiotherapy, will be monitored but will
not be included in the cost utility analysis.
Cost effectiveness will be reported in the form of an
incremental cost-effectiveness ratio. Uncertainty around
individual parameters will be explored through a series
of one-way sensitivity analyses, particularly with respect
to the unit cost of radiotherapy, which will be examined
through alternative costing methodologies [25]. Joint
uncertainty will be explored through a probabilistic
sensitivity analysis which will produce a cost-effectiveness
acceptability curve showing the probability of the interven-
tion being cost effective over a range of willingness-to-pay
thresholds, such as the £30,000 per additional QALY
currently used by NICE. As no long-term costs or benefits
are anticipated given the short life expectancy of study
patients, discounting will not be applied.
Qualitative study
Few studies have used qualitative methods to explore
patients’ experiences of esophageal cancer [7]. Only one
recent qualitative paper is available that focuses on
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no qualitative papers on stent placements in esophageal
cancer patients could be traced. Analysis of available
literature demonstrates patients shared concerns around
issues of coping. How these were constructed and
relayed differed by narrative, but the thematic finding
demonstrates the value of researching patients’ experiences
as an outcome in itself. Drawing on the experiences
of patients, the ROCS qualitative study will focus on
the following objectives: exploring patients’ motivation
for participating in the trial, exploring reasons for refusing
the trial, assessing patient experience and perceptions of
each arm of the trial, providing patient outcome data in
order to assess the feasibility of the trial design, and identi-
fying potential improvements to the recruitment process. It
is essential that the qualitative study takes place in
the pilot phase of the trial in order to address challenges
to recruitment prior to the continuation of the main trial.
Subsequent to the consent process the interviews will
be conducted at either the participant’s home or an
alternative quiet location. If a face to face interview is
not possible, telephone or video-linked interviews are
allowed where appropriate. It is anticipated that the
interview will take between 30 minutes and one hour,
however it may be stopped earlier if a patient appears
fatigued or becomes unwell.
The qualitative component of ROCS aims to recruit a
sample size of 12 to 20 patients for the experimental
arm of the trial, and 6 to 10 patients for the control arm,
with 6 to 10 non-consenting patients expected to consent
to interview on reasons for not participating in the
main trial. Non-consenters to the clinical trial will be
interviewed on one occasion whereas those participating
in the clinical trial will be interviewed three times; in
weeks one and four to capture initial decision-making
thoughts, and again at week eight to explore experiences
of the intervention process and perceptions of any benefits
or negatives experienced thus far.
Analysis of the qualitative interviews will be undertaken
using an Interpretative Phenomenological Analysis (IPA)
framework [27,28]. IPA seeks to explain the meaning that
events have for participants based on their own, everyday
social reality. Each interview will initially be analyzed in
isolation and focus on exploring how participants have
interpreted their experiences. The analysis will be under-
taken using a coding framework that will be developed
alongside the search for emerging themes that are
common across the transcripts.
The results of the analysis will be discussed and
presented with the use of narrative extracts to support
and illustrate claims and findings of the analysis. It is
intended that the TMG will analyze the results to assess
any recruitment challenges that may have been identified,
and respond with potential alterations to the trial design.The findings of the qualitative study will also, where
appropriate, be used to complement the full trial report.
Sample size considerations
In a population with a median survival of approximately
four months, an increase in median time to deterioration
in self-reported dysphagia of four weeks is considered
clinically meaningful. This is based on previous results
in Homs et al. [9] and expert multidisciplinary and
service user opinion. A survey of participating centers
demonstrated clinician accord with this. Time to event
will be calculated from the time of stent insertion to the
time of deterioration (of 11 points or more) or death.
Sample size is therefore based on a time to event analysis,
to detect an increase in median time to deterioration in
self-reported dysphagia of four weeks: from 12 to 16
weeks (equivalent to a hazard ratio (HR) of 0.75 and
a difference in 12-week event rate of 50 versus 60%).
Recruitment time will be 4.25 years with a six-month
follow-up after the final patient is recruited. For 80%
power with an alpha of 0.05 based on a two-sided log
rank test, 198 patients per arm will be required, with
396 in total, which is a total of 384 events. Assuming
20% attrition, a total of 496 patients will be required. The
degree of attrition is set at this higher level because of the
vulnerability of the patient population.
Statistical analysis
All analyses will be performed on a full intention-to-treat
basis, that is, all patients randomized will be included, and
all patients will be analyzed according to their allocated
group whatever treatment they receive. Descriptive statis-
tics of the patient characteristics within each treatment
group will be presented (including a summary of the type
of the treatment each patient actual received).
The main analysis will compare the time until self-
reported dysphagia progression between the two groups
using Kaplan-Meier curves and the log-rank test. The final
analysis will take place when 384 events (deterioration
or deaths) have been reported, which is expected to
be approximately six months after accrual closes.
Kaplan-Meier curves and log-rank tests will also be
used to compare the two groups on the secondary
outcomes of overall survival. It is possible the data
for the secondary endpoints (such as toxicity) may be
mature enough for analysis and presentation before the
main overall survival primary endpoint. The secondary out-
comes of proportions of morbidities and re-intervention
rates will be compared using a chi-square test. The area
under the curve of HRQoL scores will be compared using
t-tests adjusted for follow-up interval and survival.
The main analysis will be carried out when the required
number of events has been reached (see proposed sample
size above).
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differences in primary and secondary endpoints between
treatment groups within specific groupings based on
patient characteristics. However exploratory analysis will
be conducted to explore whether there is any consistent
benefit from using radiotherapy after a stent in different
subgroups by creating HR plots and carrying out tests for
interaction or trend based on chi-square analysis. The
statistical package STATA (StataCorp LP, Texas, USA) will
be used for all analysis and a statistical analysis plan will
be written before the data is analyzed.
Discussion
This is a challenging study of palliation in a frail patient
population with a limited prognosis. In view of the
vulnerability of the patient group and the need to
maximize data capture, this study will be conducted
in a small number of centers (10) over a longer
period of time. This will allow dedicated research staff
to promote the study adequately in each locality,
maximizing screening and recruitment and following
patient progress into the home setting - supporting
patients in completion of study measurements and
avoiding extra hospital visits. The internal pilot design in
five centers during the first year will allow assessment of
screening and recruitment processes and the success of
data capture prior to continuation to the full trial.
The HTA technology assessment of 2005 [7] conducted
a literature review which found that only 0.55% of papers
published since 1966 on esophageal cancer considered
QoL issues, despite the inherently palliative nature of
treatment options for the majority of patients. This
current study focuses on QoL and patient experience as
key outcomes. The qualitative aspect of the study is
integral to its overall design, and is essential in exploring
both the feasibility of patient recruitment, and the experi-
ence and perceived acceptability of the interventions. This
mixed methodological approach will enhance assessment
of the overall benefit for patients and the NHS of adding
palliative radiotherapy to stent placement in the context
of advanced esophageal cancer.
Trial status
The ROCS trial opened to recruitment in December
2013, with a planned recruitment period of 4.25 years.
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